Literature DB >> 26649446

Prognostic value of left ventricular reverse remodeling and performance improvement after cardiac resynchronization therapy: A prospective study.

Aymeric Menet1, Yves Guyomar2, Pierre-Vladimir Ennezat3, Pierre Graux2, Anne Laure Castel2, François Delelis2, Sébastien Heuls2, Estelle Cuvelier2, Cécile Gevaert2, Caroline Le Goffic2, Christophe Tribouilloy4, Sylvestre Maréchaux5.   

Abstract

BACKGROUND: The present study was designed to evaluate the respective value of left ventricular (LV) reverse remodeling (changes in LV end-systolic volume relative to baseline (ΔLVESV)) or LV performance improvement (ΔLV ejection fraction (ΔLVEF) or ΔGlobal longitudinal strain (GLS)) to predict long-term outcome in a prospective cohort of consecutive patients receiving routine cardiac resynchronization therapy (CRT).
METHODS: One hundred and seventy heart failure patients (NYHA classes II-IV, LVEF ≤ 35%, QRS width ≥ 120 ms) underwent echocardiography before and 9 months after CRT. The relationships between ΔLVESV, ΔLVEF, ΔGLS and outcome (all-cause mortality and/or CHF hospitalization, overall mortality, cardiovascular mortality, CHF hospitalization) were investigated.
RESULTS: During a median follow-up of 32 months, 20 patients died and 27 were hospitalized for heart failure. ΔLVESV, ΔLVEF or ΔGLS were significantly associated with all-cause mortality or CHF hospitalization (adjusted hazard's ratio (HR) per standard deviation 0.58 (0.43-0.77), 0.39 (0.27-0.57) or 0.55 (0.37-0.83) respectively, all p < 0.01) and all other endpoints (all p < 0.01). Patients with ΔLVESV≥15%, ΔLVEF ≥ 10% and ΔGLS ≥ 1% had a reduced risk of mortality or CHF hospitalization (adjusted HR=0.25 (0.12-0.51), p < 0.001, adjusted HR = 0.26 (0.13-0.54), p < 0.001 and adjusted HR 0.38 (0.19-0.75), p = 0.006 respectively). Overall performance of multivariate models was better using ΔLVESV or ΔLVEF compared with ΔGLS. Interobserver agreement was excellent for ΔLVESV (Intraclass correlation coefficient - ICC-0.91) and ΔGLS (ICC 0.90) but modest for ΔLVEF (ICC 0.76) in a sample of 20 patients from the study population.
CONCLUSIONS: LV reverse remodeling assessed by ΔLVESV is a strong and reproducible predictor of outcome following CRT. Compared with ΔLVESV, ΔLVEF and ΔGLS have important shortcomings: poorer reproducibility or lower predictive value.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac resynchronization therapy; Global longitudinal strain; Heart failure; Prognosis

Mesh:

Year:  2015        PMID: 26649446     DOI: 10.1016/j.ijcard.2015.11.091

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  Current role of echocardiography in cardiac resynchronization therapy.

Authors:  Donato Mele; Matteo Bertini; Michele Malagù; Marianna Nardozza; Roberto Ferrari
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

2.  Automated Classification of Severity in Cardiac Dyssynchrony Merging Clinical Data and Mechanical Descriptors.

Authors:  Alejandro Santos-Díaz; Raquel Valdés-Cristerna; Enrique Vallejo; Salvador Hernández; Luis Jiménez-Ángeles
Journal:  Comput Math Methods Med       Date:  2017-02-19       Impact factor: 2.238

3.  Left ventricular global longitudinal strain in predicting CRT response: one more J-shaped curve in medicine.

Authors:  Michal Orszulak; Artur Filipecki; Wojciech Wrobel; Adrianna Berger-Kucza; Witold Orszulak; Dagmara Urbanczyk-Swic; Wojciech Kwasniewski; Katarzyna Mizia-Stec
Journal:  Heart Vessels       Date:  2021-02-06       Impact factor: 2.037

4.  Global longitudinal strain as a prognostic marker in cardiac resynchronisation therapy: A systematic review.

Authors:  Vinesh Appadurai; Nicholas D'Elia; Thomas Mew; Stephen Tomlinson; Jonathan Chan; Christian Hamilton-Craig; Gregory M Scalia
Journal:  Int J Cardiol Heart Vasc       Date:  2021-07-31

5.  Cardiac remodelling predicts outcome in patients with chronic heart failure.

Authors:  Lingyu Xu; Joseph Pagano; Kelvin Chow; Gavin Y Oudit; Mark J Haykowsky; Yoko Mikami; Andrew G Howarth; James A White; Jonathan G Howlett; Jason R B Dyck; Todd J Anderson; Justin A Ezekowitz; Richard B Thompson; D Ian Paterson
Journal:  ESC Heart Fail       Date:  2021-09-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.